Gilead Sciences, Inc. GILD Archived

+25.76%
Discovered (Elapsed 97days) Discovery price $135.87 Current price $170.87 Price updated

This entry is more than 3 months old and has been archived. Prices reflect the last update.

✅ Key Summary

Gilead Sciences, Inc. is a leading biopharmaceutical company focused on the development of innovative medicines for serious diseases. The company has recently reported solid financial performance, driven by its antiviral therapies and oncology products. Despite challenges in the market, GILD's valuation remains attractive based on its growth prospects and recent stock performance.

Advertisement

🏢 Company Overview

Gilead Sciences, Inc. operates in the biopharmaceutical sector, specializing in antiviral drugs and treatments for HIV, hepatitis, and cancer. In its latest earnings report, GILD demonstrated robust revenue growth, primarily fueled by increased demand for its antiviral therapies. The company's oncology portfolio also contributed positively to its financial results. GILD's stock has shown resilience in a fluctuating market, maintaining a steady price level around $135.87 as of the last trading day. With a market capitalization of approximately $168.47 billion, Gilead remains a significant player in the industry. The company's internal basis point calculation indicates a potential investment opportunity. Analysts suggest that Gilead's strong pipeline of new drugs could further enhance its growth trajectory in the coming years.

📰 Related News

  • Gilead's New Drug Approval Boosts Market Confidence
    Positive
  • Recent Earnings Report Exceeds Analyst Expectations
    Positive
  • Market Reactions to Gilead's Strategic Partnerships
    Neutral

🏭 Competitor Comparison

  • AbbVie Inc. ABBV
    AbbVie focuses heavily on immunology and oncology, contrasting Gilead's antiviral and hepatitis portfolio.
  • Amgen Inc. AMGN
    Amgen's diverse biotechnology offerings differ from Gilead's targeted antiviral therapies.
  • Bristol-Myers Squibb Company BMY
    Bristol-Myers is more focused on cancer treatments, while Gilead excels in infectious diseases.

📅 Gilead Sciences, Inc. discovery history

This stock has been discovered 6 times.

DiscoveredDiscovery priceCurrent priceReturn
Sep 17, 2026 $150.89 $168.08 +11.39%
May 6, 2026 $136.30 $135.25 -0.77%
Apr 1, 2026 $140.30 $126.34 -9.95%
Jan 30, 2026 $141.95 $130.84 -7.83%
Dec 24, 2025 $125.67 $138.11 +9.90%
Go to the Gilead Sciences, Inc. ticker page →
Advertisement

Other recent discoveries

← Back to list